Tolmar, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.5M
Doctors Paid
9,082
Transactions
24,484
2024 Total
$2.5M
Payment Breakdown by Category
Research$7.8M (91.1%)
Food & Beverage$410,547 (4.8%)
Consulting$58,568 (0.7%)
Travel$13,078 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,872 | 91.1% |
| Food and Beverage | $410,547 | 20,366 | 4.8% |
| Honoraria | $241,518 | 115 | 2.8% |
| Consulting Fee | $58,568 | 24 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $25,500 | 3 | 0.3% |
| Travel and Lodging | $13,078 | 20 | 0.2% |
| Education | $7,637 | 1,084 | 0.1% |
Payments by Type
Research
$7.8M
2,872 transactions
General
$756,847
21,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TOL3010B | $1.9M | 0 | 381 |
| TOL2506A | $1.6M | 5 | 662 |
| Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%) in the treatment of Scalp Psoriasis | $1.4M | 0 | 241 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $873,387 | 0 | 1,065 |
| A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months | $529,422 | 0 | 131 |
| Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study | $505,584 | 0 | 162 |
| TOL2581A | $170,193 | 3 | 31 |
| A Phase 3, Single Arm, OpenLabel Study Evaluating Ovarian Suppression Following ThreeMonth Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with HormoneReceptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)Negative Breast Cancer | $164,323 | 0 | 88 |
| TOL2707A | $150,335 | 0 | 5 |
| TOL2708C | $118,140 | 0 | 20 |
| A Pivotal Pharmacokinetic Bioequivalence Study Comparing Genericto Reference Liposome-Encapsulated Doxorubicin Hydrochloride inSubjects with Epithelial Ovarian Carcinoma Who Have FailedPlatinum-Based Chemotherapy | $115,045 | 0 | 14 |
| TOL2581A-CPP | $100,953 | 3 | 35 |
| TOL2506A-EXT | $67,270 | 0 | 25 |
| TOL2649G | $67,179 | 0 | 9 |
| Calcipotriene Ointment, 0.005% and Plaque Psoriasis | $12,450 | 0 | 1 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorPositive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $8,426 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Robert Shepard, M.d, M.D | Hematology & Oncology | Raleigh, NC | $187,850 | $0 |
| Alan Rogol | Pediatrics | Charlottesville, VA | $57,059 | $0 |
| Elward Crawford, Md, MD | Urology | San Diego, CA | $16,968 | $0 |
| Dr. Scott Sellinger, Md, MD | Urology | Tallahassee, FL | $16,637 | $0 |
| Craig Alter, M.d, M.D | Pediatrics | Philadelphia, PA | $15,416 | $0 |
| Dr. Steven Finkelstein, Md, MD | Radiation Oncology | Syracuse, NY | $15,240 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $15,030 | $0 |
| Bradley Miller, M.d, M.D | Pediatrics | Minneapolis, MN | $13,740 | $0 |
| Adrian Dobs, M.d, M.D | Endocrinology, Diabetes & Metabolism | Baltimore, MD | $12,895 | $0 |
| Charles Osborne, Md, MD | Hematology & Oncology | Houston, TX | $12,200 | $0 |
| Marcela Vargas Trujillo, M.d, M.D | Pediatric Endocrinology | San Diego, CA | $11,433 | $0 |
| Karen Klein, M.d, M.D | Pediatric Endocrinology | San Diego, CA | $10,168 | $0 |
| Lawrence Silverman, Md, MD | Pediatric Endocrinology | Morristown, NJ | $8,868 | $0 |
| Dr. Sandeep Dhindsa, M.d, M.D | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $8,290 | $0 |
| Judd Moul, M.d, M.D | Urology | Durham, NC | $6,131 | $0 |
| Philippe Backeljauw, M.d, M.D | Pediatric Endocrinology | Cincinnati, OH | $5,895 | $0 |
| Diane Stafford, M.d, M.D | Pediatrics | Palo Alto, CA | $5,543 | $0 |
| Paul Kaplowitz, Md, MD | Pediatric Endocrinology | Washington, DC | $5,175 | $0 |
| Dr. Jadranka Popovic, M.d, M.D | Pediatric Endocrinology | Pittsburgh, PA | $5,065 | $0 |
| Mitchell Geffner, Md, MD | Pediatric Endocrinology | Los Angeles, CA | $4,842 | $0 |
| William Gradishar, Md, MD | Medical Oncology | Chicago, IL | $3,875 | $0 |
| Anthony Elias, Md, MD | Medical Oncology | Aurora, CO | $3,875 | $0 |
| Dr. Charles Ryan, Md, MD | Internal Medicine | Minneapolis, MN | $3,400 | $0 |
| Dr. Reema Habiby, M.d, M.D | Pediatric Endocrinology | Chicago, IL | $3,294 | $0 |
| Dr. Przemyslaw Twardowski, Md, MD | Internal Medicine | Santa Monica, CA | $2,443 | $0 |
Ad
Top Products
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
Associated Products (13)
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
- JATENZO $1.2M
- TOL3010B $1.0M
- Paliperidone Palmitate $876,180
- TOL2707A $150,335
- TOL2581A $119,766
- Doxorubicin Hydrochloride Liposome Injection- Epithelial Ovarian Carcinoma $115,045
- TOL2708C $111,095
- Eligard 45mg and CPP $100,953
- TOL2649G $67,179
- Eligard $54,537
- Calcipotriene Ointment, 0.005% and Plaque Psoriasis $12,450
Payment Categories
- Food & Beverage $410,547
- Consulting $58,568
- Travel & Lodging $13,078
- Research $7.8M
About Tolmar, Inc.
Tolmar, Inc. has made $8.5M in payments to 9,082 healthcare providers, recorded across 24,484 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is Leuprolide Acetate ($1.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Hematology & Oncology ($209,143 to 153 doctors).
Payment categories include: Food & Beverage ($410,547), Consulting ($58,568), Research ($7.8M), Travel & Lodging ($13,078).
Tolmar, Inc. is associated with 13 products in the CMS Open Payments database, including Leuprolide Acetate, Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%, and JATENZO.